key: cord-0738330-tmdvjqol
authors: Uzun, Günalp; Bohnert, Bernhard N.; Althaus, Karina; Nann, Dominik; Nadalin, Silvio; Heyne, Nils; Fend, Falko; Haap, Michael; Bakchoul, Tamam
title: Organ Donation From a Brain Dead Donor With Vaccine-induced Immune Thrombotic Thrombocytopenia After Ad26.COV2.S: The Risk of Organ Microthrombi
date: 2022-01-04
journal: Transplantation
DOI: 10.1097/tp.0000000000004039
sha: ddc5904eb90db92accb600f2cd36677aef83a455
doc_id: 738330
cord_uid: tmdvjqol

nan

in the right kidney. Further investigation depicted platelet and fibrin depositions in the glomeruli of the left kidney ( Figure 1 ). In the liver, a hemangioma and a segment with an arterial thrombosis were detected. The kidneys and the liver were refused by the respective transplantation centers. Only the heart was transplanted. The recipient of the heart did not develop thrombosis or thrombocytopenia. Anti-PF4 antibodies remained negative 3 wks after transplantation (0.270 OD).

Organ donation from deceased donors with VITT is associated with some risks, such as the presence of retained thrombi in the transplanted organ and the transmission of VITT to the recipient. 3, 5 Although our patient had normal biochemical parameters and ultrasonography of the kidneys was normal, we detected an infarction and microthrombi during further diagnostics. Furthermore, an intraluminal blood clot was detected in the liver after organ procurement. A thorough radiologic assessment of the organs with multiphase CT angiography before organ retrieval could be useful to detect hypoperfusion or infarct in organs. The extent of microthrombi and organ function should be carefully assessed before deciding whether the organ is suitable for transplantation or not.

The risk of passenger lymphocyte syndrome, which is the production of antibodies in the naive recipient by transplanted immune cells of the donor, is higher for organs with a high immune cell content, such as the lung, liver, pancreas, and small bowel. 5 So far, 1 patient was reported who developed anti-PF4 antibodies (2.3 OD) and severe thrombocytopenia after liver transplantation from a donor with VITT. 4 Platelet count recovered after IVIG therapy, and the recipient was discharged with a functioning graft. 4 Another study detected anti-PF4/heparin antibodies in 3 liver recipients; of these, 1 developed thrombosis without allograft loss. 3 Posttransplantation follow-up of the recipient should include platelet count, d-dimer, fibrinogen, and anti-PF4 antibodies. 5 Lastly, because of the prothrombotic state in patients with VITT, the donor should receive a nonheparin anticoagulant, and platelet transfusions should be avoided.

In conclusion, VITT patients should not be completely excluded as organ donors, but a thorough pretransplantation evaluation of potential risks and functionality of the showing glomerular fibrin deposition and right kidney (E and F) with fresh infarction. A, Overview with normal-looking kidney parenchyma with inconspicuous glomeruli and tubuli (H&E staining, x100 original magnification). Some glomeruli show intravascular fibrin deposits (asterisk) (B, Masson trichrome staining, x200 original magnification), containing platelets shown by CD61 staining (C, immunoperoxidase, x400 original magnification) and fibrin shown by fibrin staining (D, immunoperoxidase, x400 original magnification). E, Totally necrotic kidney parenchyma with hypereosinophilia and loss of nuclear staining infiltrated by many neutrophilic granulocytes as a reaction to the necrosis (H&E staining, x200 original magnification). F, PAS stain also shows the necrotic parenchyma (x200 original magnification). H&E, hematoxylin and eosin; PAS, Periodic acid-Schiff.

Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia

Clinical features of vaccineinduced immune thrombocytopenia and thrombosis

Organ transplantation from deceased donors with vaccine-induced thrombosis and thrombocytopenia

New-onset antibodies to platelet factor 4 following liver transplantation from a donor with vaccine-induced thrombotic thrombocytopenia

Organ donation and transplantation from patients with vaccine induced thrombosis and thrombocytopenia (VITT) (INF1569/2)